Non-Surgical Treatment of Peyronie's Disease: ESWT and Stem Cell Applications
Surgery is not the only option in Peyronie's disease. The active and stable phases, what shockwave therapy (ESWT) and stem cell applications realistically offer, which patients they suit, and when surgery comes into consideration.
Men diagnosed with Peyronie's disease usually ask the same first question: can it improve without surgery? There is no single answer, because Peyronie's is not one picture but a process with two distinct phases. The place of non-surgical methods depends precisely on that phase. This article explains what each treatment actually does, which expectations are realistic, and at what point surgery enters the discussion.
What is Peyronie's disease?
Peyronie's disease is the development of a hardened plaque (scar tissue) in the tunica albuginea, the tough sheath surrounding the penis. Because this plaque does not stretch, the penis curves towards the plaque during erection. The picture may be accompanied by pain, a sense of shortening, narrowing of the penile circumference or a decline in erection quality. The cause is not fully known, but the most widely accepted explanation is that unnoticed micro-trauma during intercourse turns into scarring in men whose wound healing is predisposed to it. Diabetes, smoking and connective tissue susceptibility increase the risk.
Why does the active phase differ from the stable phase?
- Active (inflammatory) phase: usually the first 6-12 months. There is pain, the angle of curvature changes over time and the plaque has not settled. Surgery is not performed in this period, because the shape is not yet fixed and the picture may change again after an operation. This is also largely the phase in which non-surgical approaches are tried.
- Stable phase: the pain has resolved and the curvature has remained unchanged for at least 3-6 months. Here it is not realistic to expect regenerative methods to correct the shape; if the curvature is severe enough to impair function, surgical correction is considered.
In other words, the answer to "does non-surgical treatment work" depends on which phase the patient is in.
What does shockwave therapy (ESWT) offer in Peyronie's disease?
Low-intensity shockwave therapy delivers focused pressure waves to the tissue; it requires no needles and usually no anaesthesia. What the literature consistently shows about its role in Peyronie's disease is this: ESWT provides a meaningful contribution to reducing pain, whereas there is no strong evidence that it corrects the angle of curvature or shrinks the plaque.
The typical candidate for ESWT is therefore a patient in the active phase whose pain is the leading complaint. The aim is to make a painful period more manageable and to ease the transition into the stable phase. Treatment is delivered in sessions over several weeks. It is important not to approach the patient with the expectation that "my curvature will be corrected by this treatment", as managing the process correctly depends on that clarity.
Where do stem cell and exosome applications fit?
Stem cell and exosome-based applications aim to intervene early in the formation of scar tissue and steer healing in a less fibrotic direction. Experimental studies and early clinical series contain promising signals; however, in Peyronie's disease these methods remain at the research stage. A standardised dose, an agreed protocol and large studies showing long-term outcomes are not yet sufficient.
The honest framing is this: these applications are not a way of correcting an established curvature in the stable phase. They may be considered as part of a treatment programme in the active phase, while the plaque has not yet matured. This boundary must be stated clearly to the patient; otherwise an unrealistic expectation undermines confidence in the whole treatment process.
What are all the non-surgical options?
- Oral medication: used mainly for pain management in the active phase; its effect on curvature is limited.
- Intralesional injection therapy: medication applied directly into the plaque to soften its structure. Measurable reduction in the angle of curvature has been reported in appropriately selected patients; suitability is determined by plaque characteristics and the type of curvature.
- Shockwave therapy (ESWT): primarily to reduce pain.
- Stem cell and exosome applications: in the active phase, with their research status stated openly.
- Traction (stretching) devices: among non-surgical options, this is the method with the most studied measurable effect on curvature and length. However, the effect requires several hours a day over many months; the decisive factor is whether the patient can sustain the programme.
- Vacuum devices: added to the programme as a supportive measure in some patients.
These methods are often planned not in isolation but as a combined programme tailored to the patient.
When does surgery come into consideration?
Surgical correction is evaluated once the disease has entered the stable phase and under the following conditions: the curvature is severe enough to prevent intercourse, non-surgical methods have not produced a sufficient response, there is marked narrowing in the mid-shaft (hourglass appearance), or the curvature is accompanied by significant erectile dysfunction. The technique chosen — shortening procedures, grafting over the plaque, or a penile implant in cases where erectile dysfunction also exists — is determined by the degree of curvature, penile length and erectile status.
In short, non-surgical treatments are not worthless, but they are not suitable for every patient or every phase. The right question is not "is there a non-surgical option" but "which method offers a meaningful benefit at the phase I am in". Answering it requires examination, measurement of the curvature in the erect state and, where needed, penile colour Doppler ultrasound.
Assoc. Prof. Zülfü Sertkaya practises in the field of urology and andrology in Istanbul; phase assessment and treatment planning in Peyronie's disease are carried out with individualised planning and full confidentiality.